<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483300</url>
  </required_header>
  <id_info>
    <org_study_id>BC001</org_study_id>
    <nct_id>NCT01483300</nct_id>
  </id_info>
  <brief_title>Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine plus cisplatin has been proved to be an effective regimen as second-line
      treatment for metastatic breast cancer patients, especially for those previously treated with
      anthracyclines and taxanes. Lobaplatin, as the third generation of new cancer drug platinum,
      has a similar anticancer activity to cisplatin, but less kidney toxicity and gastrointestinal
      reaction. The purpose of the study is to compare the efficacy and safety of
      gemcitabine/lobaplatin versus gemcitabine/cisplatin in patients with metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>4 weeks after chemotherapy</time_frame>
    <description>Overall response rate (ORR) defined as complete response(CR) + partial response(PR) + stable disease (SD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>one year after last patient in</time_frame>
    <description>Time to progression defined as time from randomization to disease progress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>one year after last patient in</time_frame>
    <description>Overall survival defined as time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
    <time_frame>4 weeks after chemotherapy</time_frame>
    <description>Treatment related toxicities will be recorded as chemotherapy toxicity grades in hematologic, renal, hepatic and gastrointestinal system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>lobaplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine plus lobaplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine plus cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lobaplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks</description>
    <arm_group_label>lobaplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks</description>
    <arm_group_label>cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic breast cancer

          -  Disease progression during or after previous 1st line chemotherapy

          -  Scheduled to receive 2nd line chemotherapy.

          -  Measurable disease, defined as a least one lesion that can be accurately measured in
             at least one dimension

          -  18 years of age or older

          -  ECOG performance status of 0-2

          -  Life expectancy of greater than 6 months

        Exclusion Criteria:

          -  Previous treatment with one of the study drugs

          -  Application of other cytotoxic chemotherapy or radiotherapy

          -  Insufficent renal function (creatinine clearance &lt; 60ml/min)

          -  Clinically unstable brain metastasis

          -  Pregancy or lactation

          -  History of other malignancy within last 5 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingyuan Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinmei Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingyuan Zhang, MD</last_name>
    <phone>86-451-86298276</phone>
    <email>zhma19650210@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinmei Kang, MD</last_name>
    <phone>86-451-86298683</phone>
    <email>kxm791107@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, MD</last_name>
      <phone>86-451-86298276</phone>
      <email>zhma19650210@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xinmei Kang, MD</last_name>
      <phone>86-451-86298683</phone>
      <email>kxm791107@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qingyuan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinmei Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>January 22, 2012</last_update_submitted>
  <last_update_submitted_qc>January 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Qingyuan Zhang</investigator_full_name>
    <investigator_title>Vice president of Cancer Hospital of Harbin Medical University</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>lobaplatin</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

